{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:57:42Z","timestamp":1785459462001,"version":"3.56.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.eprac.2026.06.004","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T16:30:06Z","timestamp":1781886606000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of Initiation of Semaglutide versus SGLT2 Inhibitors in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Multicenter Propensity-Matched Real-World Study"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8995-1058","authenticated-orcid":false,"given":"Ibrahim","family":"Khalil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallab","family":"Sarker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Imran","family":"Hossain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anika","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4937-5500","authenticated-orcid":false,"given":"Aizaz","family":"Anwar Khalid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananna","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joydip","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mst. Mahmuda","family":"Akter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunjida Amin","family":"Promi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Abu","family":"Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd Turzo","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5681-6522","authenticated-orcid":false,"given":"A.B.M.","family":"Kamrul-Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.eprac.2026.06.004_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2023.101133","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"29","author":"Rinella","year":"2024","journal-title":"Ann Hepatol"},{"issue":"6","key":"10.1016\/j.eprac.2026.06.004_bib2","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"9","key":"10.1016\/j.eprac.2026.06.004_bib3","first-page":"851","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.eprac.2026.06.004_bib4","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jhep.2023.03.040","article-title":"Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons","volume":"79","author":"Le","year":"2023","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.eprac.2026.06.004_bib5","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.eprac.2026.06.004_bib6","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/hep.28709","article-title":"Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives","volume":"65","author":"Arab","year":"2017","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"1","key":"10.1016\/j.eprac.2026.06.004_bib7","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12916-018-1103-x","article-title":"Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease","volume":"16","author":"Alexander","year":"2018","journal-title":"BMC Med"},{"key":"10.1016\/j.eprac.2026.06.004_bib8","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1111\/jgh.14585","article-title":"Characteristics of non-alcoholic steatohepatitis among lean patients in Japan: Not uncommon and not always benign","volume":"34","author":"Tobari","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.eprac.2026.06.004_bib9","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1002\/hep.29546","article-title":"Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year-community study","volume":"67","author":"Allen","year":"2018","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"8","key":"10.1016\/j.eprac.2026.06.004_bib10","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1053\/j.gastro.2016.02.066","article-title":"Pathogenesis of Nonalcoholic Steatohepatitis","volume":"150","author":"Machado","year":"2016","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.eprac.2026.06.004_bib11","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1177\/1756283X16638830","article-title":"Lifestyle changes for the treatment of nonalcoholic fatty liver disease: a review of observational studies and intervention trials","volume":"9","author":"Zelber-Sagi","year":"2016","journal-title":"Ther Adv Gastroenterol"},{"issue":"6","key":"10.1016\/j.eprac.2026.06.004_bib12","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.eprac.2026.06.004_bib14","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eprac.2026.06.004_bib15","article-title":"Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD practice guidance","author":"Bansal","year":"2025","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"22","key":"10.1016\/j.eprac.2026.06.004_bib16","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.eprac.2026.06.004_bib17","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eprac.2026.06.004_bib18","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.aed.2025.08.007","article-title":"Evaluating the comparative effectiveness of sodium-glucose transporter 2 inhibitors in patients with nonalcoholic fatty liver disease: a comprehensive systematic review and bayesian network meta-analysis of randomized controlled trials","volume":"12","author":"Khalil","year":"2025","journal-title":"AACE Endocrinol Diabetes"},{"key":"10.1016\/j.eprac.2026.06.004_bib19","series-title":"Platform Overview and Compliance: HIPAA\/GDPR Adherence","year":"2025"},{"issue":"9596","key":"10.1016\/j.eprac.2026.06.004_bib20","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet (London, England)"},{"issue":"3","key":"10.1016\/j.eprac.2026.06.004_bib21","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/dom.13955","article-title":"Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk","volume":"22","author":"Husain","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"24","key":"10.1016\/j.eprac.2026.06.004_bib22","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.eprac.2026.06.004_bib23","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes","volume":"392","author":"McGuire","year":"2025","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.eprac.2026.06.004_bib24","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jhep.2010.09.032","article-title":"Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase","volume":"54","author":"Ben-Shlomo","year":"2011","journal-title":"J Hepatol"},{"issue":"35","key":"10.1016\/j.eprac.2026.06.004_bib25","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1093\/eurheartj\/ehac384","article-title":"Dual glucose-dependent insulinotropic polypeptide\/glucagon-like peptide-1 receptor agonism for substantial body weight reduction in obese subjects","volume":"43","author":"Liuzzo","year":"2022","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.eprac.2026.06.004_bib26","first-page":"111","article-title":"Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis","volume":"15","author":"Jia","year":"2018","journal-title":"Nat Rev"},{"issue":"7","key":"10.1016\/j.eprac.2026.06.004_bib27","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1053\/j.gastro.2019.11.311","article-title":"Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis","volume":"158","author":"Schwabe","year":"2020","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.eprac.2026.06.004_bib28","first-page":"653","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.eprac.2026.06.004_bib29","doi-asserted-by":"crossref","first-page":"6008","DOI":"10.1097\/MS9.0000000000003658","article-title":"Comparative efficacy of sodium-glucose transporter 2 inhibitors on lipid profiles in nonalcoholic fatty liver disease (NAFLD): a comprehensive Bayesian network meta-analysis","volume":"87","author":"Khalil","year":"2025","journal-title":"Ann Med Surg"},{"key":"10.1016\/j.eprac.2026.06.004_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2022.109791","article-title":"Dapagliflozin for nonalcoholic fatty liver disease: A systematic review and meta-analysis","volume":"185","author":"He","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"10.1016\/j.eprac.2026.06.004_bib31","article-title":"Impact of SGLT2i and GLP-1RA on liver-related events in patients with MASLD and type 2 diabetes: A network meta-analysis","volume":"8","author":"Li","year":"2026","journal-title":"JHEP Rep"},{"issue":"1","key":"10.1016\/j.eprac.2026.06.004_bib32","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"Paul","year":"1983","journal-title":"Biometrika"},{"issue":"8","key":"10.1016\/j.eprac.2026.06.004_bib33","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"2","key":"10.1016\/j.eprac.2026.06.004_bib34","doi-asserted-by":"crossref","first-page":"24","DOI":"10.71079\/ASIDE.IM.03222516","article-title":"TriNetX and real-world evidence: a critical review of its strengths, limitations, and bias considerations in clinical research","volume":"1","author":"Nassar","year":"2025","journal-title":"ASIDE Intern Med"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26010384?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26010384?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:58:51Z","timestamp":1785455931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X26010384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":33,"alternative-id":["S1530891X26010384"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2026.06.004","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of Initiation of Semaglutide versus SGLT2 Inhibitors in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Multicenter Propensity-Matched Real-World Study","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2026.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}